TY - JOUR
AU - Lambert I. J. C. Bergers
AU - Christianne M. A. Reijnders
AU - Lenie J. van den Broek
AU - Sander W. Spiekstra
AU - Tanja D. de Gruijl
AU - Ester M. Weijers
AU - Susan Gibbs
AB - All skin diseases have an underlying immune component. Owing to differences in animal and human immunology, the majority of drugs fail in the preclinical or clinical testing phases. Therefore animal alternative methods that incorporate human immunology into in vitro skin disease models are required to move the field forward. This review summarizes the progress, using examples from fibrosis, autoimmune diseases, psoriasis, cancer and contact allergy. The emphasis is on co-cultures and 3D organotypic models. Our conclusion is that current models are inadequate and future developments with immune-competent skin-on-chip models based on induced pluripotent stem cells could provide a next generation of skin models for drug discovery and testing.
BT - Drug Discovery Today
DA - 2016-09
DO - 10.1016/j.drudis.2016.05.008
IS - 9
N2 - All skin diseases have an underlying immune component. Owing to differences in animal and human immunology, the majority of drugs fail in the preclinical or clinical testing phases. Therefore animal alternative methods that incorporate human immunology into in vitro skin disease models are required to move the field forward. This review summarizes the progress, using examples from fibrosis, autoimmune diseases, psoriasis, cancer and contact allergy. The emphasis is on co-cultures and 3D organotypic models. Our conclusion is that current models are inadequate and future developments with immune-competent skin-on-chip models based on induced pluripotent stem cells could provide a next generation of skin models for drug discovery and testing.
PY - 2016
SP - 1479
EP - 1488
T2 - Drug Discovery Today
TI - Immune-competent human skin disease models
UR - https://www.sciencedirect.com/science/article/pii/S1359644616301581
VL - 21
Y2 - 2024-08-13
SN - 1359-6446
ER -